PBIRx, a prominent pharmacy benefit consulting firm based in Shelton, Connecticut, recently conducted a webinar titled 'Biosimilars: The New Savings Frontier.' The session focused on the substantial cost savings that biosimilars can provide, with potential reductions of up to 90% compared to traditional specialty drugs. Despite these significant savings, the adoption of biosimilars in the United States has been relatively slow. During the webinar, PBIRx President Patricia Sirowich emphasized the need for better utilization of biosimilars to combat the rising costs of specialty medications. The expert panel, which included pharmacists Andrew Reis, Marc Shapiro, and Angela Medeiros, shared valuable insights and strategies aimed at enhancing biosimilar adoption among plan sponsors. They discussed tools and trends that can help lower overall plan costs while ensuring optimal health outcomes for members. PBIRx, founded in 1993, has established itself as a leader in independent pharmacy benefit auditing and consulting, holding SOC 2 Type 2 and SOC 3 attestation reports, and is recognized on the Inc. 5000 list of fastest-growing companies.